B of A Securities Maintains Buy on Rhythm Pharmaceuticals, Lowers Price Target to $139

Benzinga Newsdesk www.benzinga.com Neutral 62.5%

Neg 0% Neu 62.5% Pos 0%

B of A Securities analyst Tazeen Ahmad maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and lowers the price target from $145 to $139.